pharma · Primary Sclerosing Cholangitis (PSC) · No medical condition.
Dr. Falk Pharma
Dr. Falk Pharma GmbH
Dr. Falk Pharma is a pharma organization headquartered in Freiburg im Breisgau, DE. Primary therapeutic focus areas include Primary Sclerosing Cholangitis (PSC), No medical condition., eosinophilic esophagitis, Celiac Di
Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE HQ
399 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Leinenweberstraße 5, Freiburg im Breisgau, Baden-Württemberg 79108, DE
- Employees
- 399
- Programs
- 11
- Drugs
- 15
- Patents
- 0
NUC01, Placebo to NUC01
Phase 3 · small molecule · primary sclerosing cholangitis (PSC)
NUC01, Placebo to NUC01 for primary sclerosing cholangitis (PSC) is a Phase 3 program (small_molecule) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code NUC-5/PSC
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dr. Falk Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- primary sclerosing cholangitis (PSC)
- Status
- active
- Trials
- 1